CHARGED ALPHA
Stock Analysis
Stock Library / KRYS
KRYS Healthcare Latest YouTube: Q1 2026

healthcare

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest earnings video

KRYS Stock: Revenue Up 10% — Q1 2026 Earnings Analysis

Library coverage

Episodes tracked
1
Episodes linked
1
Latest video
Q1 2026
Podcast available
Yes
Current price
$375.40
+7.09 (+1.93%)
Trailing / Forward P/E
50.19x
Forward: 37.26x
Market cap / Volume
Volume:
Revenue / Earnings Growth
31.9%
Earnings: 52.5%
Margins
46.1% op
Gross: 94.2% · Net: 53.9%
Balance sheet
9.46x current
Debt / Equity: 0.7
52-week range / Beta
$130.50 - $382.54
Beta: 0.50
Analyst target
$349.78
Upside: -6.8%
Cash / shareholder return
1.24% FCF yield
Dividend yield: —

Company context

Industry: Biotechnology
Country: United States
Employees:
Price to book: 8.66x
Return on equity: 19.9%
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Price chart

Market context for KRYS

Competitive view

KRYS vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

healthcare latest YouTube video thumbnail YouTube
healthcare
KRYS
Latest video
Q1 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Intuitive Surgical latest YouTube video thumbnail YouTube
Intuitive Surgical
ISRG
Latest video
Q1 2026
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Johnson & Johnson latest YouTube video thumbnail YouTube
Johnson & Johnson
JNJ
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.
Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
KRYS
$11.07B
healthcare
ISRG
$147.01B
Intuitive Surgical
JNJ
$634.06B
Johnson & Johnson
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
KRYS
50.2x
healthcare
ISRG
50.3x
Intuitive Surgical
JNJ
30.5x
Johnson & Johnson
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
KRYS
37.3x
healthcare
ISRG
35.2x
Intuitive Surgical
JNJ
20.7x
Johnson & Johnson
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
KRYS
31.9%
healthcare
ISRG
23.0%
Intuitive Surgical
JNJ
9.9%
Johnson & Johnson
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
KRYS
52.5%
healthcare
ISRG
18.8%
Intuitive Surgical
JNJ
-52.9%
Johnson & Johnson
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
KRYS
46.1%
healthcare
ISRG
30.9%
Intuitive Surgical
JNJ
27.4%
Johnson & Johnson
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
KRYS
94.2%
healthcare
ISRG
66.3%
Intuitive Surgical
JNJ
68.0%
Johnson & Johnson
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
KRYS
53.9%
healthcare
ISRG
28.2%
Intuitive Surgical
JNJ
21.8%
Johnson & Johnson
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
KRYS
19.9%
healthcare
ISRG
17.2%
Intuitive Surgical
JNJ
26.4%
Johnson & Johnson
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
KRYS
1.2%
healthcare
ISRG
1.5%
Intuitive Surgical
JNJ
2.0%
Johnson & Johnson
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
KRYS
0.71x
healthcare
ISRG
Intuitive Surgical
JNJ
67.73x
Johnson & Johnson
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
KRYS
9.46x
healthcare
ISRG
4.61x
Intuitive Surgical
JNJ
1.02x
Johnson & Johnson
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
KRYS
0.50
healthcare
ISRG
1.46
Intuitive Surgical
JNJ
0.23
Johnson & Johnson
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
KRYS
healthcare
ISRG
Intuitive Surgical
JNJ
1.9%
Johnson & Johnson
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
KRYS
-6.8%
healthcare
ISRG
35.7%
Intuitive Surgical
JNJ
-2.1%
Johnson & Johnson

Episode timeline

Episode archive for KRYS

Each row is one earnings episode with every verified platform link available.

Q1 2026
Episode live
Published youtube podcast complete
KRYS Stock: Revenue Up 10% — Q1 2026 Earnings Analysis
Quarterly earnings-analysis entry for healthcare. Use the links on the right to open the video or podcast episode.